DOP2022000095A - Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con nmp con navitoclax - Google Patents

Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con nmp con navitoclax

Info

Publication number
DOP2022000095A
DOP2022000095A DO2022000095A DO2022000095A DOP2022000095A DO P2022000095 A DOP2022000095 A DO P2022000095A DO 2022000095 A DO2022000095 A DO 2022000095A DO 2022000095 A DO2022000095 A DO 2022000095A DO P2022000095 A DOP2022000095 A DO P2022000095A
Authority
DO
Dominican Republic
Prior art keywords
navitoclax
mpn
myelofibrosis
treatment
related disorders
Prior art date
Application number
DO2022000095A
Other languages
English (en)
Inventor
Hayslip John
Holes Leanne
Mensing Sven
Nuthalapati Silpa
Original Assignee
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland filed Critical Abbvie Deutschland
Publication of DOP2022000095A publication Critical patent/DOP2022000095A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención descrita en el presente documento se refiere a métodos para tratar a un sujeto humano con mielofibrosis o un trastorno relacionado con NMP, que comprende la administración de navitoclax al sujeto, opcionalmente en combinación con ruxolitinib.
DO2022000095A 2019-11-05 2022-05-05 Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con nmp con navitoclax DOP2022000095A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930951P 2019-11-05 2019-11-05
US202062984518P 2020-03-03 2020-03-03
PCT/US2020/058910 WO2021092030A1 (en) 2019-11-05 2020-11-04 Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax

Publications (1)

Publication Number Publication Date
DOP2022000095A true DOP2022000095A (es) 2022-07-31

Family

ID=73449255

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2022000095A DOP2022000095A (es) 2019-11-05 2022-05-05 Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con nmp con navitoclax

Country Status (13)

Country Link
US (2) US11285159B2 (es)
EP (1) EP4054585A1 (es)
JP (1) JP2022553820A (es)
KR (1) KR20220098755A (es)
CN (1) CN115279375A (es)
AU (1) AU2020378279A1 (es)
BR (1) BR112022008683A2 (es)
CA (1) CA3160091A1 (es)
CL (1) CL2022001177A1 (es)
DO (1) DOP2022000095A (es)
IL (1) IL292713A (es)
MX (1) MX2022005375A (es)
WO (1) WO2021092030A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115279375A (zh) * 2019-11-05 2022-11-01 艾伯维公司 用于以navitoclax治疗骨髓纤维化和mpn相关病症的给药方案

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
MX2007014049A (es) 2005-05-12 2008-02-11 Abbott Lab Activadores de apoptosis.
US7713170B2 (en) 2006-07-31 2010-05-11 Hyundai Motor Company Shift control method of automatic transmission
US8748108B2 (en) 2006-09-05 2014-06-10 Abbvie Inc. Biomarkers for identifying patient classes
US20080193943A1 (en) 2006-09-05 2008-08-14 Abbott Laboratories Companion diagnostic assays for cancer therapy
US20080233567A1 (en) 2006-09-05 2008-09-25 Murray William E Companion diagnostic assays for cancer therapy
CA2662320C (en) 2006-09-05 2014-07-22 Abbott Laboratories Bcl inhibitors treating platelet excess
US20100087436A1 (en) 2006-11-16 2010-04-08 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
US20080182845A1 (en) 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
AU2007329458A1 (en) 2006-12-04 2008-06-12 Abbott Laboratories Companion diagnostic assays for cancer therapy
US20100028889A1 (en) 2006-12-04 2010-02-04 Abbott Laboratories Companion diagnostic assays for cancer therapy
WO2008082673A2 (en) 2006-12-28 2008-07-10 Abbott Laboratories Companion diagnostic assays for cancer therapy
RU2472509C2 (ru) 2007-11-16 2013-01-20 Эбботт Лэборетриз Способ лечения артрита
WO2009073835A1 (en) 2007-12-06 2009-06-11 Abbott Laboratories Oral compositions of abt-263 for treating cancer
US8277804B2 (en) 2008-05-21 2012-10-02 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
NO2367570T3 (es) 2008-11-25 2018-05-19
US20190083665A1 (en) 2008-11-25 2019-03-21 Alderbio Holdings Llc Antibodies to il-6 and use thereof
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US20100280031A1 (en) 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI471321B (zh) 2009-06-08 2015-02-01 Abbott Gmbh & Co Kg Ｂｃｌ－２族群抑制劑之口服醫藥劑型
RU2012101627A (ru) 2009-06-18 2013-07-27 Эбботт Лэборетриз Стабильная суспензия лекарственного средства в виде наночастиц
CN102695702A (zh) 2009-09-20 2012-09-26 雅培制药有限公司 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
WO2011066378A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to prevent or treat thrombosis
CA2780177A1 (en) 2009-12-22 2011-06-30 Abbott Laboratories Abt-263 capsule
SG182016A1 (en) 2010-12-14 2012-07-30 Univ Singapore Method of detecting resistance to cancer therapy
WO2014004376A2 (en) 2012-06-26 2014-01-03 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
US20150283142A1 (en) 2013-03-15 2015-10-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
EP2914296B2 (en) 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US20150313906A1 (en) 2012-12-19 2015-11-05 Glaxosmithkline Llc Combination
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
CA2904743A1 (en) 2013-03-14 2014-09-25 Alder Biopharmaceuticals, Inc. Antibodies to hgf and compositions containing
US9446064B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. Combination therapy for treating cancer
JP2016517434A (ja) 2013-03-14 2016-06-16 エピザイム，インコーポレイティド 癌を処置するための併用療法
US9732150B2 (en) 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
CA2914284A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2015095834A2 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using erk1/2 and bcl-2 family inhibitors
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
SG10201805670QA (en) 2014-01-28 2018-08-30 Buck Inst Res Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
WO2015157120A1 (en) 2014-04-06 2015-10-15 Abraxis Bioscience, Llc Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
WO2016043874A2 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Combination therapy for treating cancer
WO2017060431A1 (en) * 2015-10-09 2017-04-13 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
RU2022108295A (ru) 2016-06-22 2022-04-06 Эллипсес Фарма Лтд Способы лечения ar+ рака молочной железы
US10668078B2 (en) 2016-07-28 2020-06-02 Children's Hospital Medical Center Methods and compositions for treating mesothelioma and small lung cancer that express midkine
CN106177955B (zh) 2016-08-18 2018-03-16 广州威溶特医药科技有限公司 Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
RU2019127350A (ru) 2017-02-03 2021-03-03 ЭйАй ТЕРАПЬЮТИКС, ИНК. Способы лечения рака с использованием ингибиторов hsp90
TR201703149A2 (tr) 2017-03-01 2018-09-21 Univ Yeditepe Kemoterapi̇k i̇laç kompozi̇syonu
JP6617208B2 (ja) 2017-03-31 2019-12-11 ノバルティス アーゲー 血液腫瘍におけるｈｄｍ２−ｐ５３相互作用阻害剤の用量およびレジメン
US11672800B2 (en) * 2017-04-21 2023-06-13 Epizyme, Inc. Combination therapies with EHMT2 inhibitors
US11179412B2 (en) * 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
WO2019178433A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
US11317646B2 (en) 2018-08-18 2022-05-03 Louis Dischler Methods and compositions for rapidly decreasing epigenetic age and restoration of more youthful function
AU2019343044A1 (en) 2018-09-18 2021-03-18 Signalchem Lifesciences Corporation Combination therapy for treating blood cancer
WO2020092117A2 (en) 2018-10-30 2020-05-07 Unity Biotechnology, Inc. Killing senescent cells and treating senescence-associated diseases or disorders using a combination of a bcl inhibitor and an mcl-1 inhibitor
WO2020132184A1 (en) 2018-12-19 2020-06-25 University Of Maryland, Baltimore Asparaginase-induced glutamine depletion combined with bcl-2 inhibition for treatment of hematologic and solid cancers
CN113194952A (zh) 2018-12-20 2021-07-30 诺华股份有限公司 Hdm2-p53相互作用抑制剂和bcl2抑制剂的组合及其治疗癌症的用途
CA3142361A1 (en) 2019-06-12 2020-12-17 Juno Therapeutics, Inc. Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
CN115279375A (zh) * 2019-11-05 2022-11-01 艾伯维公司 用于以navitoclax治疗骨髓纤维化和mpn相关病症的给药方案

Also Published As

Publication number Publication date
BR112022008683A2 (pt) 2022-07-19
US20210128573A1 (en) 2021-05-06
AU2020378279A1 (en) 2022-05-26
MX2022005375A (es) 2022-10-07
KR20220098755A (ko) 2022-07-12
CA3160091A1 (en) 2021-05-14
CL2022001177A1 (es) 2023-01-20
IL292713A (en) 2022-07-01
CN115279375A (zh) 2022-11-01
JP2022553820A (ja) 2022-12-26
WO2021092030A1 (en) 2021-05-14
US20230019186A1 (en) 2023-01-19
US11285159B2 (en) 2022-03-29
EP4054585A1 (en) 2022-09-14

Similar Documents

Publication Publication Date Title
GT201700246A (es) Métodos y kits para tratar la depresión
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
SV2017005380A (es) Tratamientos conjuntos con anticuerpos anti cd40
BR112017025166A2 (pt) métodos de condicionar pacientes para terapia de células t
MX2019012818A (es) Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
CR20190468A (es) Métodos para tratar enfermedades y trastornos mediados por completo
BR112018013733A2 (pt) combinações anti-cd20 para o tratamento de tumores a
BR112019008384A2 (pt) composição farmacêutica, processos para tratamento e seus usos
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
BR112019001039A2 (pt) composição para uso no tratamento de transtorno depressivo maior
MX2018013663A (es) Metodos para tratar trastornos de sueño de ritmo circadiano.
MX2017011486A (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
BR112018008882A2 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
EA201991650A1 (ru) Способы лечения неврологических расстройств
DOP2022000095A (es) Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con nmp con navitoclax
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
EA201790352A1 (ru) Терапевтическое лечение на основе анаморелина
BR112019008241A2 (pt) tratamento do prurigo nodular
AR113983A1 (es) Tratamiento de desórdenes autónomos
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
AR106313A1 (es) Combinación de levodopa deuterada con carbidopa y opicapona para el tratamiento de enfermedad de parkinson
MX2021011598A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.
BR112021010856A2 (pt) Vibegron para o tratamento de sintomas de bexiga hiperativa
AR122344A1 (es) Uso de reboxetina para tratar desórdenes del sistema nervioso